Imbalance in glycemic control between the treatment and placebo groups in cardiovascular outcome trials in type 2 diabetes

BACKGROUND: Glycated hemoglobin (HbA1c) is accepted as the most reliable marker for assessing chronic glycemia. The present study aimed to investigate glycemic control in cardiovascular outcome trials (CVOTs) performed by pharmaceutical sponsors, at the request of the United States Food and Drug Adm...

Descripción completa

Detalles Bibliográficos
Autores principales: Shimazawa, Rumiko, Ikeda, Masayuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6859615/
https://www.ncbi.nlm.nih.gov/pubmed/31832207
http://dx.doi.org/10.1186/s40545-019-0193-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6859615/
https://www.ncbi.nlm.nih.gov/pubmed/31832207
http://dx.doi.org/10.1186/s40545-019-0193-y

Ejemplares similares